Clear All
12611 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
83831-0164-10 83831-0164 Fluorouracil FAVLYXA 25.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jul 15, 2026 In Use
83831-0183-04 83831-0183 Bendamustine hydrochloride BENDAMUSTINE HYDROCHLORIDE 100.0 mg/4mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 29, 2026 In Use
83858-0101-60 83858-0101 Dasatinib PHYRAGO 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0102-60 83858-0102 Dasatinib PHYRAGO 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0103-60 83858-0103 Dasatinib PHYRAGO 70.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0104-30 83858-0104 Dasatinib PHYRAGO 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0105-30 83858-0105 Dasatinib PHYRAGO 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Aug 1, 2024 In Use
83980-0012-13 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-01 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-83 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0012-10 83980-0012 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-13 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-10 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-01 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0013-83 83980-0013 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jun 19, 2025 In Use
83980-0017-97 83980-0017 Ondansetron hydrochloride Ondansetron hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
83980-0017-13 83980-0017 Ondansetron hydrochloride Ondansetron hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
83980-0017-10 83980-0017 Ondansetron hydrochloride Ondansetron hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
83980-0018-10 83980-0018 Ondansetron hydrochloride Ondansetron hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
83980-0018-97 83980-0018 Ondansetron hydrochloride Ondansetron hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
83980-0018-13 83980-0018 Ondansetron hydrochloride Ondansetron hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug 14, 2026 In Use
84043-0100-30 84043-0100 Vepdegestrant VEPPANU 100.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, Cereblon/CRBN Oral May 1, 2026 In Use
84043-0200-30 84043-0200 Vepdegestrant VEPPANU 200.0 mg/1 Hormonal Therapy Proteolysis Targeting Chimera (PROTAC) ER, cereblon/CRBN Oral May 1, 2026 In Use
84386-0009-03 84386-0009 Isotretinoin Isotretinoin 20.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sep 10, 2026 In Use

Found 12611 results — Export these results